Sodium-Glucose Transporter-2 Inhibitors NewsLatest News On Sodium-Glucose Transporter-2 Inhibitors Risk-Directed Management Key in Optimizing CKD Therapy2/7/2025 8:39 AM Empagliflozin May Slow Diabetic Retinopathy12/6/2024 7:39 AM Bariatric Surgery Better Than Obesity Drugs for Some Patients With MASLD11/25/2024 4:06 AM Diabetes Drug Class May Reduce Need for Gout Medications11/19/2024 8:03 AM SGLT2 Inhibitor Adoption for Heart Failure Rises in the US, But Varies Across Hospitals11/19/2024 6:55 AM Intranasal Insulin Drug Combo Promising for Alzheimer’s11/6/2024 1:57 AM Empagliflozin Effects Subside With Discontinuation10/27/2024 8:23 PM Rise in GLP-1 RA and SGLT2 Inhibitor Prescribing in Patients With T1D10/24/2024 8:00 AM SGLT2 Inhibitors Associated With Better Survival in PAH10/8/2024 7:33 AM Finerenone Fills a Therapeutic Gap in Heart Failure9/12/2024 2:37 PM Do SGLT2 Inhibitors Benefit Everyone With T2D and CKD?9/10/2024 9:48 AM The New Report Cards: Your Patient's CGM Data7/22/2024 1:53 PM Does Medicare Enrollment Raise Diabetes Medication Costs?7/11/2024 1:28 AM FLOW: GLP-1 Kidney Benefits Seen With or Without SGLT2 Inhibitors6/25/2024 11:29 AM Glucagon Blocker and SGLT2 Inhibitor: Winning Combo in T1D?6/20/2024 7:03 AM Updated Guideline Reflects New Drugs for Type 2 Diabetes6/18/2024 4:42 AM SGLT2s With Diuretics Improve Heart Failure Outcomes6/7/2024 3:15 PM SGLT2 Inhibitors Add to GLP-1s' Cardio, Kidney Benefits6/3/2024 1:17 AM What's the Goal in Treating Type 2 Diabetes?5/23/2024 2:50 PM SGLT2 Inhibitors Reduce Anemia Risk in Concomitant T2D, CKD4/11/2024 6:58 AM
